Ameritas Investment Partners
CLYM icon

Ameritas Investment Partners’s Climb Bio CLYM Stock Holding History

Ameritas Investment Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7K Buy
+3,197
New +$33K ﹤0.01% 2356
2025
Q2 		– Sell
-2,981
Closed -$3.64K – 3380
2025
Q1 		$3.64K Hold
2,981
– – ﹤0.01% 3025
2024
Q4 		$5.37K Hold
2,981
– – ﹤0.01% 3016
2024
Q3 		$15.2K Buy
2,981
+2,267
+318% +$16K ﹤0.01% 2773
2024
Q2 		$5.08K Buy
+714
New +$4.75K ﹤0.01% 3030
2022
Q2 		– Sell
-541
Closed -$5K – 3265
2022
Q1 		$5K Hold
541
– – ﹤0.01% 2976
2021
Q4 		$6K Hold
541
– – ﹤0.01% 3021
2021
Q3 		$10K Buy
+541
New +$11.2K ﹤0.01% 2947

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameritas Investment Partners's CLYM Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in Climb Bio (CLYM) in Q2 2026: 3,197 shares worth $41.7K. The stake represents ﹤0.01% of the portfolio and ranks #2356 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in CLYM as recently as Q1 2025.

Ameritas Investment Partners first reported a position in CLYM in Q3 2021 and has held it in 8 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Ameritas Investment Partners held 3,197 shares of Climb Bio worth $41.7K as of Q2 2026.
  • Climb Bio was a new Ameritas Investment Partners position in Q2 2026.
  • Climb Bio made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2356 holding.
  • Ameritas Investment Partners first reported a position in Climb Bio in Q3 2021 and has held it in 8 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.